NGR018: Randomized Phase II Study of NGR-hTNF Plus Pegylated Liposomal Doxorubicin (PLD) Versus PLD in Platinum-resistant Ovarian Cancer.

Trial Profile

NGR018: Randomized Phase II Study of NGR-hTNF Plus Pegylated Liposomal Doxorubicin (PLD) Versus PLD in Platinum-resistant Ovarian Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs NGR-TNF (Primary) ; Doxorubicin; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors MolMed
  • Most Recent Events

    • 26 Jan 2017 This trial has been completed in Italy.
    • 01 Apr 2015 Planned End Date changed from 1 Feb 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
    • 01 Apr 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top